Clinical and neurophysiological effects of topiramate in chronic migraine
- 作者: Shevchenko V.1, Artemenko A.1, Kurenkov A.2, Bzhllyansky M.3, Bushkov F.3
-
隶属关系:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Research Medical Center for Children’s Health, Ministry of Health of Russia
- Preodolenie (Overcoming) Rehabilitation Center
- 期: 卷 29, 编号 11 (2018)
- 页面: 66-69
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/117392
- DOI: https://doi.org/10.29296/25877305-2018-11-14
- ID: 117392
如何引用文章
详细
全文:
作者简介
V. Shevchenko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: vladashevchenko@list.ru
A. Artemenko
I.M. Sechenov First Moscow State Medical University (Sechenov University)
A. Kurenkov
Research Medical Center for Children’s Health, Ministry of Health of Russia
M. Bzhllyansky
Preodolenie (Overcoming) Rehabilitation CenterCandidate of Medical Sciences
F. Bushkov
Preodolenie (Overcoming) Rehabilitation CenterCandidate of Medical Sciences
参考
- Olesen J. International Classification of Headache Disorders // Lancet Neurol. - 2018; 17 (5): 396-7. doi: 10.1016/S1474-4422(18)30085-1.
- Bigal M., Lipton R. Concepts and mechanisms of migraine chronification // Headache. - 2008; 48 (1): 7-15. doi: 10.1111/j.1526-4610.2007.00969.
- Aurora S., Brin M. Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies // Headache. - 2017; 57 (1): 109-25. doi: 10.1111/head.12999.
- Su M., Yu S. Chronic migraine: A process of dysmodulation and sensitization // Mol. Pain. - 2018; 14: doi: 10.1177/1744806918767697.
- Mulleners W., Chronicle E., Palmer J. et al. Suppression of perception in migraine: evidence for reduced inhibition in visual cortex // Neurology. - 2001; 56 (2): 178-83. doi:org/10.1212/WNL.56.2.178.
- Aurora S., al-Sayeed F., Welch K. The cortical silent period is shortened in migraine with aura // Cephalalgia. - 1999; 19 (8): 708-12. doi: 10.1046/j.1468-2982.1999.019008708.x.
- Curra A., Pierelli F., Coppola G. et al. Shortened cortical silent period in facial muscles of patients with migraine // Pain. - 2007; 132 (1-2): 124-31. doi: 10.1016/j.pain.2007.05.009.
- Brighina F., Giglia G., Scalia S. et al. Facilitatory effects of 1 Hz rTMS in motor cortex of patients affected by migraine with aura // Exp. Brain Res. - 2005; 161 (1): 34-8. doi: 10.1007/s00221-004-2042-7.
- Xu X., Liu Y., Dong M. et al. Tricyclic antidepressants for preventing migraine in adults // Medicine (Baltimore). - 2017; 96 (22): e6989. DOI: 10.1097/ MD.0000000000006989.
- Азимова Ю.Э., Скоробогатых К.В., Сергеев А.В. и лр. Эффективность и безопасность терапии антидепрессантами мигрени и депрессии // Журн. неврол. и психиат. им. С.С. Корсакова. - 2016; 116 (11): 35-40. doi. org/10.17116/jnevro201611611135-40.
- Loder E., Rizzoli P. Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018 // Headache. - 2018; doi: 10.1111/ head.13375.
- Linde K., Rossnagel K. WITHDRAWN: Propranolol for migraine prophylaxis // Cochrane Database Syst. Rev. - 2017; 2: CD003225. doi: 10.1002/14651858. CD003225.pub3
- Артеменко А.Р., Куренков А.Л., Никитин С.С. и др. Ботулинический нейротоксин и хроническая мигрень: хемоденервация мышечных волокн или модуляция ноцицептивной системы? // Нервно-мышечные болезни. - 2013; 4: 6-11. doi.org/10.17650/2222-8721-2013-0-4-6-12.
- Cernuda-Morollön E., Martinez-Camblor P., Ramön C. et. al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine // Headache. - 2014; 54 (6): 987-95. doi: 10.1111/head.12372.
- Cernuda-Morollön E., Ramön C., Martinez-Camblor P. et al. Onabotulinum toxin A decreases interictal CGRP plasma levels in patients with chronic migraine // Pain. - 2015; 156 (5): 820-4. doi: 10.1097/j.pain.0000000000000119.
- Bagnato F., Good J. The Use of Antiepileptics in Migraine Prophylaxis // Headache. - 2016; 56 (3): 603-15. doi: 10.1111/head.12781.
- Silberstein S. Topiramate in Migraine Prevention: A 2016 Perspective // Headache. - 2017; 57 (1): 165-78. doi: 10.1111/head.12997.
- Rogawski M., Löscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions // Nat. Med. - 2004; 10 (7): 685-92. doi: 10.1038/nm1074.
- Artemenko A., Kurenkov A., Filatova E. et al. Effects of topiramate on migraine frequency and cortical excitability in patients with frequent migraine // Cephalalgia. - 2008; 28 (3): 203-8. doi: 10.1111/j.1468-2982.2007.01491.x.
- Артеменко А.Р. Куренков А.Л. Хроническая мигрень / М.: АБВ-пресс, 2012; 488 с.
- The International Classification of Headache Disorders, 3rd edition (beta version).Headache Classification Committee of the International Headache Society // Cephalalgia. - 2013; 33 (9): 629-808. doi: 10.1177/0333102413485658.
- Rossini P., Burke D., Chen R. et al. Non-invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: Basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee // Clin. Neurophysiol. - 2015; 126: 1071-107. doi: 10.1016/j.clinph.2015.02.001.
- Young W., Shaw J., Bloom M. et al. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects // Headache. - 2008; 48: 1490-8. doi: 10.1111/j.1526-4610.2008.01292.x.
- Mulleners W., Chronicle E., Vredeveld J. et al. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS // Eur. J. Neurol. - 2002; 9: 35-40. PMID: 11784374.
- Gerwig M., Niehaus L., Kastrup O. et al. Beta-blocker migraine prophylaxis affects the excitability of the visual cortex as revealed by transcranial magnetic stimulation // J. Headache Pain. - 2012; 13 (1): 83-9. doi: 10.1007/s10194-011-0401-x.